2 unchanged sentences
Rule 10b5-1 Trading Plans
−Removed: During the three months ended September 30, 2025 , none of our directors or officers adopted , materially modified , or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.
+Added: During the three months ended March 31, 2026 , none of our directors or officers adopted , materially modified , or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.
Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc.
1 unchanged sentence
001-39385) filed on February 23, 2023).
−Removed: Amended and Restated Bylaws of Relay Therapeutics, Inc.
+Added: Second Amended and Restated Bylaws of Relay Therapeutics, Inc.
(incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No.
−Removed: 001-39385) filed on July 21, 2020).
+Added: 001-39385) filed on March 11, 2026).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
RELAY THERAPEUTICS, INC.
−Removed: November 6, 2025
/S/ SANJIV K.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 6, 2025
/S/ THOMAS CATINAZZO
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.